Is it safe to administer methergine (methylergonovine) with oxytocin to a patient undergoing a cesarean section without a history of hypertension or preeclampsia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Methergine with Oxytocin at Cesarean Section

Methergine (methylergonovine) should NOT be routinely administered with oxytocin during cesarean section in patients without hypertension or preeclampsia, as it is contraindicated due to significant risk (>10%) of vasoconstriction and hypertension. 1, 2

Primary Recommendation

  • The European Society of Cardiology explicitly states that methylergonovine is contraindicated in the postpartum period because of the risk (>10%) of vasoconstriction and hypertension. 1, 2

  • Oxytocin remains the first-line uterotonic agent for prevention and treatment of postpartum hemorrhage during cesarean delivery. 3, 4

Appropriate Oxytocin Administration Protocol

  • Administer oxytocin as a slow intravenous infusion (<2 U/min or approximately 33 mU/min) after placental delivery to avoid systemic hypotension. 1, 2

  • Avoid rapid IV bolus administration of oxytocin, as this can cause severe hypotension, tachycardia, and uterine hyperstimulation. 2

  • For elective cesarean sections in nonlaboring women, the effective dose (ED90) is approximately 0.35-0.5 IU as initial bolus, followed by continuous infusion of 40 mU/min. 5

  • Continuous infusion of low doses is preferred over bolus administration to minimize cardiovascular side effects. 3, 4

When Additional Uterotonics Are Needed

If oxytocin alone fails to achieve adequate uterine contraction:

  • Prostaglandin F analogues (such as carboprost) are useful alternatives for treating postpartum hemorrhage, unless an increase in pulmonary artery pressure is undesirable. 1

  • Tranexamic acid (1g IV over 10 minutes) should be administered early (within 3 hours of birth) for clinically diagnosed postpartum hemorrhage, regardless of whether bleeding is due to uterine atony or trauma. 1

  • A second dose of tranexamic acid (1g IV) may be given if bleeding continues after 30 minutes or restarts within 24 hours. 1

Critical Monitoring Requirements

  • Pulse oximetry and continuous ECG monitoring should be utilized as clinically indicated for patients receiving oxytocin. 2

  • Hemodynamic monitoring must be continued for at least 24 hours after delivery due to significant fluid shifts that may precipitate complications. 1, 2

  • Systemic arterial pressure and maternal heart rate require continuous monitoring during oxytocin administration. 1

Common Pitfall to Avoid

The most critical error is administering methylergonovine routinely with oxytocin "for better uterine contraction." This practice exposes patients to unnecessary risk of severe hypertension and vasoconstriction without evidence of benefit when oxytocin is properly dosed. 1, 2 Methylergonovine should be reserved only for refractory cases of uterine atony where oxytocin and prostaglandins have failed, and only after careful consideration of contraindications.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Oxytocin Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Oxytocin in cesarean sections: what is the best way to use it?].

Revista brasileira de anestesiologia, 2007

Research

Oxytocin in cesarean-sections. What's new?

Brazilian journal of anesthesiology (Elsevier), 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.